ArticleFrontiers in endocrinology2025
Trabecular bone score in the assessment of bone health in thalassemia major.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thalassemia major (TM) has a significant impact on patients' quality of life. Osteoporosis and osteopenia are common and important complications, yet they are often underestimated. Their etiology is multifactorial, culminating in reduced bone mass, impaired remodeling, and increased fracture risk. The reported prevalence of osteopenia and osteoporosis in TM is highly variable, reaching up to 90%. The trabecular bone score (TBS) is a relatively recent analytical tool that measures lumbar spine texture on dual X-ray absorptiometry (DXA) images. At present, only limited data are available on its use in TM. The aim of this retrospective study was to assess bone health in TM and to evaluate the TBS as a potential diagnostic and prognostic tool. Methods: Eighty-eight adult outpatients with TM (mean age: 41.9 ± 8.9 years) were enrolled. The following parameters were evaluated: laboratory tests, DXA measurements, and thoracic-lumbar spine X-rays (assessed by Genant's method). Results: Reduced BMD was observed in 96.3% of patients. TBS values were also markedly reduced; however, their performance in discriminating fractures in this cohort appeared to have limited clinical utility. Discussion: The TBS may be a valuable, non-invasive complementary tool for assessing bone quality alongside BMD, although it does not reliably discriminate between patients with and without fractures. Further investigations are needed to clarify the role of the TBS in predicting fracture risk in TM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.